LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease
- 9th Edition - October 20, 2020
- Author: Deepak L. Bhatt
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 6 7 3 6 1 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 6 7 3 6 2 - 4
Authoritative, portable, and up to date, Opie’s Cardiovascular Drugs, 9th Edition, is the definitive reference for quick access to frequently used drugs in all phases of care for… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAuthoritative, portable, and up to date, Opie’s Cardiovascular Drugs, 9th Edition, is the definitive reference for quick access to frequently used drugs in all phases of care for cardiac patients. Now a part of the Braunwald family of renowned cardiology references, this compact title provides crucial information in an easily accessible format—ideal for cardiologists, residents, cardiology fellows, medical students, nurses, and other cardiac care providers. Updated to include the latest guidelines and evidence-based implications, it offers clear and concise explanations and pertinent clinical facts for all classes of cardiac drugs, as well as all the latest clinical trial results and evidence for the pharmacologic treatment of heart disease.
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Foreword
- Preface
- Acknowledgments
- Braunwald’s Heart Disease Family of Books
- 1: Drugs for Ischemic Heart Disease
- Introduction
- β-Blockers
- Summary
- Nitrates and Newer (or Nontraditional) Antianginals
- Calcium Channel Blockers
- Summary
- Summary
- 2: Antihypertensive Therapies
- Introduction
- Drug Class Overview and Guidelines
- Diuretics
- Calcium Channel Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin II Receptor Blockers
- Mineralocorticoid Receptor Antagonists
- β-Blockers
- Central Sympatholytic Agents
- α1-Adrenoreceptor Antagonists
- Direct Vasodilators
- 3: Heart Failure
- Introduction
- Acute Decompensated Heart Failure
- Pharmacotherapy
- Vasodilators
- Novel Vasodilators
- Inotropes
- β-Adrenergic Agonists
- Phosphodiesterase Inhibitors
- Calcium Sensitizers
- Novel Inotropes
- Vasopressors
- Special Situations
- Heart Failure Patients With Reduced Ejection Fraction
- Pharmacotherapy
- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Receptor Blockers
- Angiotensin Receptor Neprilysin Inhibitors
- Mineralocorticoid-Receptor Antagonists
- Sodium-Glucose Cotransporter-2 Inhibitors
- Additional Therapy
- Combination of Hydralazine Plus Isosorbide Dinitrate
- If Channel Inhibitor
- Digoxin
- Iron Supplementation and Anemia
- Fish Oil and Marine Omega-3 Polyunsaturated Fatty Acids
- Micronutrient Supplementation
- Oral Anticoagulants and Antiplatelet Therapy
- Statins
- Antiarrhythmic Agents
- Direct Renin Inhibitors
- Heart Failure Patients With Preserved Ejection Fraction
- Heart Failure Patients With Mid-Range Ejection Fraction
- Pharmacotherapy
- Renin-Angiotensin Blockade: Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
- Mineralocorticoid Receptor Antagonists
- Angiotensin Receptor Neprilysin Inhibitors
- β-Blockers
- Digoxin, Calcium Channel Blockers, and Ivabradine
- Nitric Oxide and cGMP Signaling: Phosphodiesterase-5 Inhibitors, Nitrates, and Soluble Guanylate Cyclase Stimulators
- Other Medications
- Reverse Cardiac Remodeling: Remission Versus Recovery
- Drugs That Should Be Avoided or Used Cautiously in Heart Failure
- Pharmacological Treatment of Selected Cardiomyopathies
- Future Perspectives
- Summary
- 4: Drugs for Diabetes
- Metabolic Syndrome and Prediabetes
- Diabetes Prevention
- Cardiovascular Disease Risk Assessment
- Value of Improved Glycemic Control
- Importance of Large Cardiovascular Disease Outcome Trials
- Drugs That Lower Cardiovascular Disease Risk
- Drugs That Do Not Lower Cardiovascular Disease Risk
- Hypoglycemia
- Guidelines
- Future Directions
- 5: Drugs for Obesity
- Drug Class Overview and Guidelines
- Weight Loss Intervention
- Pathophysiology and Mechanism of Action
- Conclusion
- 6: Lipid-Modifying Drugs
- Inflammation and Atherogenesis
- Prevention and Risk Factors
- Blood Lipid Profile
- Lipids in Special Population Groups
- Dietary and Other Nondrug Therapy for Dyslipidemia
- Drug Therapy for Dyslipidemia
- Summary
- 7: Drugs Targeting Inflammation
- Basic Concepts of Inflammation Biology
- Stimuli for the Inflammatory Response
- Central Hubs of Inflammatory Signaling (see Fig. 7.2)
- Mediators
- Conclusions, Challenges, and Future Perspective
- 8: Antithrombotic Drugs
- Introduction
- Thrombosis
- Emerging Construct and Future Targets for Antithrombotic Therapy
- Cardiovascular Drug Therapy
- Platelet-Directed Therapies
- Platelet P2Y12 Receptor Antagonists
- Periprocedural Management of Antiplatelet Therapy
- Intravenous Platelet GPIIb/IIIa Receptor Antagonists
- Summary of Recommendations in Patients With ACS
- Anticoagulants
- Parenteral Anticoagulant Drugs
- Direct Thrombin Inhibitors
- Direct FXa Inhibitors
- Indirect, Selective FXa Inhibitors
- Direct Thrombin Inhibitors
- Argatroban
- Reversal and Replacement Therapy for Parenteral Anticoagulants
- Oral Anticoagulant Drugs
- Pharmacokinetics and Drug Disposition
- Oral Direct Thrombin Inhibitors
- Vitamin K Antagonists
- Reversal and Replacement of Direct Oral Anticoagulant Drugs
- Achieving Good Hemostasis
- Conclusions
- 9: Antiarrhythmic Drugs
- Overview of New Developments
- Antiarrhythmic Drugs
- Inhaled Agents
- New Developments in Antiarrhythmics
- Antiarrhythmic Choice for Arrhythmias
- Summary
- 10: Vascular Medicine Drugs
- Overview
- 11: Drugs for Pulmonary Hypertension
- Drug Class Overview and Guidelines
- Mechanisms of Action
- Differences Among Drugs in Class
- Data for Use
- Side Effects
- Drug Interactions
- Experimental Drugs
- Conclusions
- Index
- No. of pages: 720
- Language: English
- Edition: 9
- Published: October 20, 2020
- Imprint: Elsevier
- Paperback ISBN: 9780323673617
- eBook ISBN: 9780323673624
DB
Deepak L. Bhatt
Deepak L. Bhatt, MD, MPH, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. A leading authority internationally on interventional cardiology in addition
Affiliations and expertise
Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart and Vascular Center; Professor of Medicine, Harvard Medical School, Boston, Massachusetts, USA